US9125910 — 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Method of Use · Assigned to H Lundbeck AS · Expires 2027-06-15 · 1y remaining
What this patent protects
This patent protects a method of treating Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD) using a therapeutically effective amount of Compound I, 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
USPTO Abstract
This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2309 |
— | vortioxetine-hydrobromide |
U-2309 |
— | vortioxetine-hydrobromide |
U-2309 |
— | vortioxetine-hydrobromide |
U-2309 |
— | vortioxetine-hydrobromide |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.